Science Explorer Back to mapMap
Discussion
Researcher · Leo Pharma (Denmark) · Denmark

Karsten Petersson

Karsten Petersson publishes mostly in Pharmaceutical Science, Molecular Biology and Dermatology, on topics such as Advancements in Transdermal Drug Delivery, Advanced Drug Delivery Systems and RNA Interference and Gene Delivery.

OpenAlex
World rank
#1,486,500
of 7,710,434 ranked researchers
Rank in Denmark
#11,220
of 43,819
Works
24
Citations
2k
Citations per work
82.0
h-index
13
i10-index 15Top 49% in Pharmaceutical Science
Karsten Petersson

What does Karsten Petersson research?

Karsten Petersson's work is mostly in Pharmacology, Toxicology and Pharmaceutics (29%), Biochemistry, Genetics and Molecular Biology (20%), Medicine (14%).

Life Sciences: 13 works · 54.3% of their workPharmacology, Toxicology and Pharmaceutics: 7 works · 28.6% of their workPharmaceutical Science: 7 works · 28.6% of their workBiochemistry, Genetics and Molecular Biology: 5 works · 20.0% of their workMolecular Biology: 5 works · 20.0% of their workImmunology and Microbiology: 1 works · 5.7% of their workImmunology: 1 works · 5.7% of their workEverything else: 7 works · 27.1% of their workHealth Sciences: 3 works · 14.3% of their workMedicine: 3 works · 14.3% of their workDermatology: 2 works · 10.0% of their workPulmonary and Respiratory Medicine: 1 works · 4.3% of their workPhysical Sciences: 1 works · 4.3% of their workEngineering: 1 works · 4.3% of their workBiomedical Engineering: 1 works · 4.3% of their workTHEIR WORKKarsten Petersson24works
Life Sciences54%Physical Sciences4%Health Sciences14%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Pharmacology, Toxicology and Pharmaceutics728.6%
    2. Biochemistry, Genetics and Molecular Biology520.0%
    3. Immunology and Microbiology15.7%
  2. Everything else727.1%
    1. Medicine314.3%
    1. Engineering14.3%
  1. 1Pharmaceutical Science29% of their works
  2. 2Molecular Biology20% of their works
  3. 3Dermatology10% of their works
  4. 4Immunology6% of their works
  5. 5Pulmonary and Respiratory Medicine4% of their works
  6. 6Biomedical Engineering4% of their works

Research topics

Which keywords describe Karsten Petersson's research?

The keywords of their largest research topics: Microneedles, Solid Lipid Nanoparticles, Chitosan, Nanoparticles, Filaggrin, RNA Interference, siRNA Delivery and Skin Microbiome.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most.

All 16 words, with their numbers
  1. Microneedles121 topic
  2. Solid Lipid Nanoparticles121 topic
  3. Chitosan61 topic
  4. Nanoparticles61 topic
  5. Filaggrin41 topic
  6. RNA Interference41 topic
  7. Skin Microbiome41 topic
  8. siRNA Delivery41 topic
  9. Lipid Rafts31 topic
  10. Membrane Lipids31 topic
  11. Cyclodextrins21 topic
  12. Dendritic Cells21 topic
  13. Immunity21 topic
  14. Matrix Metalloproteinases21 topic
  15. Solid Dispersions21 topic
  16. Tissue Inhibitors of Metalloproteinases21 topic

Where does Karsten Petersson work?

Karsten Petersson's main affiliation in the publication record is Leo Pharma (Denmark), Denmark.

How many publications and citations does Karsten Petersson have?

OpenAlex counts 24 works and 1,967 citations for Karsten Petersson, an h-index of 13, ranking #1,486,500 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Karsten Petersson. Posts are plain text and can be reported.